Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis
Status:
Completed
Trial end date:
2006-11-28
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to assess the clinical efficacy of Rebif® 44 microgram
(mcg) three times per week compared with Copaxone® 20 milligram (mg) daily in subjects with
relapsing Multiple Sclerosis.